Sagimet Biosciences Inc. SGMT, announced Monday the terms of its initial public offering. The California-based biopharmaceutical firm focused on developing treatments to treat nonalcoholic steatohepatitis is looking to raise $79.7 millions. The company will offer 4.69 million shares at a price of between $15 and $17 per share. Pricing would put the company’s value at $366.35 millions. Goldman Sachs TD Cowen Piper Sandler JMP Securities and JMP Securities will be the underwriters. The stock should list on the Nasdaq under the ticker “SGMT”. The company lost $6.5 million in the first quarter on zero revenue, compared to a loss $8.7 millions on zero revenue a year earlier. The company wants to go public when the Renaissance IPO exchange traded fund IPO +0.34% is up 15.3% in the last three months, while the S&P500 SPX +0.06% is up 7.1%.